News | Cardiovascular Clinical Studies | June 20, 2024

HonorHealth Research Institute Study Uses New Programing for Pacemakers to Control High Blood Pressure Without Additional Drugs

Dr. Rahul Doshi leads ‘BACKBEAT’ clinical trial to prevent strokes and heart attacks by precisely timing heartbeats

Dr. Rahul Doshi leads ‘BACKBEAT’ clinical trial to prevent strokes and heart attacks by precisely timing heartbeats

June 20, 2024 — A programming algorithm, being tested by HonorHealth Research Institute for those patients with new or recently installed pacemakers, is designed so the device not only provides a steady heartbeat, but also controls high blood pressure.

A recently opened clinical trial called BACKBEAT (BradycArdia paCemaKer for Blood prEssure treAtmenT) aims to use Medtronic’s Astra and Azure model pacemakers to not only treat slow heart rates but also delivers electrical pulses stimulating the heart in a way that reduces the patient’s blood pressure.

The clinical trial is for patients who require a pacemaker, but who no longer respond well to their current high blood pressure medication.

“It’s a huge, huge health problem,” said Rahul Doshi, M.D., an electrophysiologist in the Research Institute’s Cardiovascular Research Division. “Many patients who require a pacemaker have uncontrolled high blood pressure”.

The electrical system of the heart works by coordinating the function of the upper chambers (the atria) and the lower chambers (the ventricles) in order to function as a pump delivering blood to the whole body.

By varying the timing of heart beats for the upper and lower chambers, the new algorithm can lower blood pressure by several mechanisms and have a lasting benefit. Reducing high blood pressure lowers the risk of life-threatening strokes, heart attacks and cardiovascular diseases.

 

Method provides lasting benefit

“This therapy works automatically without the patient or the doctor having to do anything. You just turn it on, and it works,” Dr. Doshi said. “It’s very promising. It’s been demonstrated in all of our preliminary data that, not only does this work, but it also has a lasting benefit if you continue the therapy.”

Previous attempts to cultivate a non-drug method of controlling high blood pressure did not provide a lasting effect, Dr. Doshi said.

For more information: www.honorhealth.com

 

Related content:

Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients

Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT for the Treatment of Hypertension in Pacemaker Patients

Orchestra BioMed Announces Presentation of Positive Long-Term Clinical Results from MODERATO II Control Patients Crossover Extension Study of BackBeat CNT at TCT 2022 

Pacemaker for Hypertension Shows Significant Clinical Impact 

Significant and Sustained Reduction in Blood Pressure in MODERATO II Trial Using BackBeat Cardiac Neuromodulation Therapy in Crossover Patients 

MODERATO II Study: Cardiac Neuromodulation Significantly Reduces Systolic Blood Pressure 

BackBeat Cardiac Neuromodulation Therapy Shows Immediate, Substantial Blood Pressure Reduction

 


Related Content

News | Hypertension

June 28, 2024 — AstraZeneca has set out a new ambition for Healthy Heart Africa, its flagship health equity initiative ...

Home June 28, 2024
Home
News | Hypertension

June 6, 2024 — A substantial portion of young athletes are at risk of hypertension, according to a study presented at ...

Home June 06, 2024
Home
News | Hypertension

May 16, 2024 — People were more likely to develop a type of treatment-resistant hypertension when they experienced ...

Home May 16, 2024
Home
News | Hypertension

May 8, 2024 — Ultrasound could one day complement or even replace drugs to treat diseases. Bioelectronic medicine ...

Home May 08, 2024
Home
News | Hypertension

April 1, 2024 — Sleeping fewer than seven hours is associated with a higher risk of developing high blood pressure over ...

Home April 01, 2024
Home
News | Hypertension

March 18, 2024 — The Smidt Heart Institute at Cedars-Sinai recently became one of four institutions in the U.S. and the ...

Home March 18, 2024
Home
News | Hypertension

February 27, 2024 — Aria CV, Inc, a developer of medical devices treating pulmonary hypertension, today announced the ...

Home February 27, 2024
Home
News | Hypertension

February 14, 2024 — The replacement of regular salt with a salt substitute can reduce incidences of hypertension, or ...

Home February 14, 2024
Home
News | Hypertension

January 19, 2024 — Orchestra BioMed, a biomedical company accelerating high-impact technologies to patients through risk ...

Home January 19, 2024
Home
News | Hypertension

December 13, 2023 —Infusions of potentially therapeutic cells derived from the heart are safe for people with pulmonary ...

Home December 13, 2023
Home
Subscribe Now